Which has higher valuation and earnings, RMNI or MXCT?

Rimini Street has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rimini Street $421.54M 1.06 $37.10M $0.08 60.18 MaxCyte $33.03M 3.52 -$44.63M -$0.37 N/A

Is RMNI or MXCT more profitable?

Rimini Street has a net margin of 1.69% compared to MaxCyte's net margin of -121.16%. MaxCyte's return on equity of -20.03% beat Rimini Street's return on equity. Company Net Margins Return on Equity Return on Assets Rimini Street 1.69% -49.20% 3.22% MaxCyte -121.16% -20.03% -17.14%

Do analysts prefer GRVY or MXCT?

MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 360.83%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than GRAVITY. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRAVITY 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 MaxCyte 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, GRVY or MXCT?

GRAVITY has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than GRAVITY, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAVITY $388.04M 1.11 $47.22M $7.30 8.50 MaxCyte $33.03M 3.52 -$44.63M -$0.37 N/A

Is GRVY or MXCT more profitable?

GRAVITY has a net margin of 12.63% compared to MaxCyte's net margin of -121.16%. GRAVITY's return on equity of 11.44% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets GRAVITY 12.63% 11.44% 9.68% MaxCyte -121.16% -20.03% -17.14%

Which has preferable valuation and earnings, PSFE or MXCT?

MaxCyte has lower revenue, but higher earnings than Paysafe. MaxCyte is trading at a lower price-to-earnings ratio than Paysafe, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Paysafe $1.74B 0.24 -$182.51M -$3.53 N/A MaxCyte $33.03M 3.52 -$44.63M -$0.37 N/A

Is PSFE or MXCT more profitable?

Paysafe has a net margin of -11.44% compared to MaxCyte's net margin of -121.16%. Paysafe's return on equity of 11.32% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Paysafe -11.44% 11.32% 1.66% MaxCyte -121.16% -20.03% -17.14%

Which has higher valuation & earnings, CTEV or MXCT?

MaxCyte has lower revenue, but higher earnings than Claritev. MaxCyte is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Claritev $978.76M 0.41 -$284.28M -$17.33 N/A MaxCyte $33.03M 3.52 -$44.63M -$0.37 N/A

Is CTEV or MXCT more profitable?

Claritev has a net margin of -29.27% compared to MaxCyte's net margin of -121.16%. Claritev's return on equity of 0.00% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets Claritev -29.27% N/A -4.36% MaxCyte -121.16% -20.03% -17.14%

Which has preferable earnings & valuation, MXCT or TRVG?

Trivago N.V. ADS has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Trivago N.V. ADS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 3.52 -$44.63M -$0.37 N/A Trivago N.V. ADS $620.90M 0.62 $12.69M $0.05 109.70

Is MXCT or TRVG more profitable?

Trivago N.V. ADS has a net margin of 2.10% compared to MaxCyte's net margin of -121.16%. Trivago N.V. ADS's return on equity of 7.39% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -121.16% -20.03% -17.14% Trivago N.V. ADS 2.10% 7.39% 4.25%

MaxCyte (MXCT) Competitors

$1.08 +0.04 (+3.33%)

As of 10:25 AM Eastern

Compare

MXCT vs. RMNI, GRVY, PSFE, CTEV, and TRVG

Should you buy MaxCyte stock or one of its competitors? MarketBeat compares MaxCyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MaxCyte include Rimini Street (RMNI), GRAVITY (GRVY), Paysafe (PSFE), Claritev (CTEV), and Trivago N.V. ADS (TRVG).

How does MaxCyte compare to Rimini Street?

Rimini Street (NASDAQ:RMNI) and MaxCyte (NASDAQ:MXCT) are related small-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Rimini Street has a net margin of 1.69% compared to MaxCyte's net margin of -121.16%. MaxCyte's return on equity of -20.03% beat Rimini Street's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rimini Street	1.69%	-49.20%	3.22%
MaxCyte	-121.16%	-20.03%	-17.14%

In the previous week, Rimini Street had 16 more articles in the media than MaxCyte. MarketBeat recorded 16 mentions for Rimini Street and 0 mentions for MaxCyte. Rimini Street's average media sentiment score of 0.44 beat MaxCyte's score of 0.00 indicating that Rimini Street is being referred to more favorably in the media.

Company	Overall Sentiment
Rimini Street	Neutral
MaxCyte	Neutral

Rimini Street has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Rimini Street currently has a consensus price target of $5.00, suggesting a potential upside of 3.86%. MaxCyte has a consensus price target of $5.00, suggesting a potential upside of 360.83%. Given MaxCyte's higher possible upside, analysts plainly believe MaxCyte is more favorable than Rimini Street.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rimini Street	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

73.8% of Rimini Street shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 42.0% of Rimini Street shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rimini Street has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rimini Street	$421.54M	1.06	$37.10M	$0.08	60.18
MaxCyte	$33.03M	3.52	-$44.63M	-$0.37	N/A

Summary

Rimini Street beats MaxCyte on 11 of the 15 factors compared between the two stocks.

How does MaxCyte compare to GRAVITY?

GRAVITY (NASDAQ:GRVY) and MaxCyte (NASDAQ:MXCT) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

GRAVITY has a net margin of 12.63% compared to MaxCyte's net margin of -121.16%. GRAVITY's return on equity of 11.44% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAVITY	12.63%	11.44%	9.68%
MaxCyte	-121.16%	-20.03%	-17.14%

In the previous week, GRAVITY had 2 more articles in the media than MaxCyte. MarketBeat recorded 2 mentions for GRAVITY and 0 mentions for MaxCyte. GRAVITY's average media sentiment score of 0.96 beat MaxCyte's score of 0.00 indicating that GRAVITY is being referred to more favorably in the media.

Company	Overall Sentiment
GRAVITY	Positive
MaxCyte	Neutral

GRAVITY has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 360.83%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than GRAVITY.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAVITY	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GRAVITY has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than GRAVITY, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAVITY	$388.04M	1.11	$47.22M	$7.30	8.50
MaxCyte	$33.03M	3.52	-$44.63M	-$0.37	N/A

9.9% of GRAVITY shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

GRAVITY beats MaxCyte on 9 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Paysafe?

Paysafe (NYSE:PSFE) and MaxCyte (NASDAQ:MXCT) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

MaxCyte has lower revenue, but higher earnings than Paysafe. MaxCyte is trading at a lower price-to-earnings ratio than Paysafe, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paysafe	$1.74B	0.24	-$182.51M	-$3.53	N/A
MaxCyte	$33.03M	3.52	-$44.63M	-$0.37	N/A

Paysafe currently has a consensus target price of $9.88, suggesting a potential upside of 22.75%. MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 360.83%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Paysafe.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paysafe	3 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Paysafe had 6 more articles in the media than MaxCyte. MarketBeat recorded 6 mentions for Paysafe and 0 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.00 beat Paysafe's score of -0.09 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Paysafe	Neutral
MaxCyte	Neutral

Paysafe has a net margin of -11.44% compared to MaxCyte's net margin of -121.16%. Paysafe's return on equity of 11.32% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Paysafe	-11.44%	11.32%	1.66%
MaxCyte	-121.16%	-20.03%	-17.14%

54.4% of Paysafe shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Paysafe has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

Summary

MaxCyte beats Paysafe on 8 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Claritev?

Claritev (NYSE:CTEV) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

87.2% of Claritev shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 7.4% of Claritev shares are owned by insiders. Comparatively, 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Claritev had 2 more articles in the media than MaxCyte. MarketBeat recorded 2 mentions for Claritev and 0 mentions for MaxCyte. Claritev's average media sentiment score of 0.13 beat MaxCyte's score of 0.00 indicating that Claritev is being referred to more favorably in the media.

Company	Overall Sentiment
Claritev	Neutral
MaxCyte	Neutral

Claritev has a net margin of -29.27% compared to MaxCyte's net margin of -121.16%. Claritev's return on equity of 0.00% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Claritev	-29.27%	N/A	-4.36%
MaxCyte	-121.16%	-20.03%	-17.14%

Claritev has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

MaxCyte has lower revenue, but higher earnings than Claritev. MaxCyte is trading at a lower price-to-earnings ratio than Claritev, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Claritev	$978.76M	0.41	-$284.28M	-$17.33	N/A
MaxCyte	$33.03M	3.52	-$44.63M	-$0.37	N/A

Claritev presently has a consensus price target of $34.50, indicating a potential upside of 46.12%. MaxCyte has a consensus price target of $5.00, indicating a potential upside of 360.83%. Given MaxCyte's higher possible upside, analysts plainly believe MaxCyte is more favorable than Claritev.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Claritev	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Claritev beats MaxCyte on 11 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Trivago N.V. ADS?

MaxCyte (NASDAQ:MXCT) and Trivago N.V. ADS (NASDAQ:TRVG) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Trivago N.V. ADS has a net margin of 2.10% compared to MaxCyte's net margin of -121.16%. Trivago N.V. ADS's return on equity of 7.39% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-20.03%	-17.14%
Trivago N.V. ADS	2.10%	7.39%	4.25%

Trivago N.V. ADS has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Trivago N.V. ADS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.52	-$44.63M	-$0.37	N/A
Trivago N.V. ADS	$620.90M	0.62	$12.69M	$0.05	109.70

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 4.5% of Trivago N.V. ADS shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 6.5% of Trivago N.V. ADS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MaxCyte presently has a consensus target price of $5.00, indicating a potential upside of 360.83%. Trivago N.V. ADS has a consensus target price of $4.09, indicating a potential downside of 25.48%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than Trivago N.V. ADS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trivago N.V. ADS	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.83

MaxCyte has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Trivago N.V. ADS has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

In the previous week, Trivago N.V. ADS had 5 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Trivago N.V. ADS and 0 mentions for MaxCyte. Trivago N.V. ADS's average media sentiment score of 0.60 beat MaxCyte's score of 0.00 indicating that Trivago N.V. ADS is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Neutral
Trivago N.V. ADS	Positive

Summary

Trivago N.V. ADS beats MaxCyte on 10 of the 16 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$116.23M	$9.16B	$6.81B	$12.55B
Dividend Yield	N/A	1.47%	2.59%	10.03%
P/E Ratio	-2.93	59.18	282.12	24.83
Price / Sales	3.52	275.34	573.08	78.59
Price / Cash	N/A	25.63	28.60	46.71
Price / Book	0.67	5.10	11.02	6.15
Net Income	-$44.63M	$57.47B	$3.49B	$347.61M
7 Day Performance	6.37%	1.04%	0.47%	1.17%
1 Month Performance	-10.70%	-3.28%	-4.24%	-3.46%
1 Year Performance	-46.81%	15.80%	62.63%	19.43%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	3.1355 of 5 stars	$1.09 +3.3%	$5.00 +360.8%	-48.5%	$116.23M	$33.03M	N/A	80
RMNI Rimini Street	2.3422 of 5 stars	$4.79 -2.5%	$5.00 +4.5%	+15.6%	$442.90M	$421.54M	12.93	1,980	Analyst Upgrade Gap Down
GRVY GRAVITY	1.7139 of 5 stars	$61.52 -0.7%	N/A	+0.5%	$427.56M	$388.04M	8.43	340	Upcoming Earnings Short Interest Decrease
PSFE Paysafe	1.7913 of 5 stars	$8.13 -4.1%	$9.88 +21.5%	-29.2%	$419.82M	$1.74B	N/A	2,900	News Coverage Analyst Downgrade Gap Down
CTEV Claritev	2.6125 of 5 stars	$23.15 -1.8%	$34.50 +49.0%	-40.8%	$394.66M	$978.76M	N/A	3,000	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. RMNI, GRVY, PSFE, CTEV, and TRVG

How does MaxCyte compare to Rimini Street?

Summary

How does MaxCyte compare to GRAVITY?

Summary

How does MaxCyte compare to Paysafe?

Summary

How does MaxCyte compare to Claritev?

Summary

How does MaxCyte compare to Trivago N.V. ADS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. RMNI, GRVY, PSFE, CTEV, and TRVG

How does MaxCyte compare to Rimini Street?

Is RMNI or MXCT more profitable?

Does the media refer more to RMNI or MXCT?

Which has more volatility and risk, RMNI or MXCT?

Do analysts recommend RMNI or MXCT?

Do insiders & institutionals hold more shares of RMNI or MXCT?

Which has higher valuation and earnings, RMNI or MXCT?

Summary

How does MaxCyte compare to GRAVITY?

Is GRVY or MXCT more profitable?

Does the media favor GRVY or MXCT?

Which has more volatility and risk, GRVY or MXCT?

Do analysts prefer GRVY or MXCT?

Which has higher earnings and valuation, GRVY or MXCT?

Do institutionals and insiders hold more shares of GRVY or MXCT?

Summary

How does MaxCyte compare to Paysafe?

Which has preferable valuation and earnings, PSFE or MXCT?

Do analysts prefer PSFE or MXCT?

Does the media refer more to PSFE or MXCT?

Is PSFE or MXCT more profitable?

Do institutionals & insiders hold more shares of PSFE or MXCT?

Which has more risk & volatility, PSFE or MXCT?

Summary

How does MaxCyte compare to Claritev?

Do institutionals and insiders have more ownership in CTEV or MXCT?

Does the media prefer CTEV or MXCT?

Is CTEV or MXCT more profitable?

Which has more risk & volatility, CTEV or MXCT?

Which has higher valuation & earnings, CTEV or MXCT?

Do analysts recommend CTEV or MXCT?

Summary

How does MaxCyte compare to Trivago N.V. ADS?

Is MXCT or TRVG more profitable?

Which has preferable earnings & valuation, MXCT or TRVG?

Do insiders & institutionals believe in MXCT or TRVG?

Do analysts prefer MXCT or TRVG?

Which has more risk and volatility, MXCT or TRVG?

Does the media favor MXCT or TRVG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools